WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK
| Autor: | Mainz, J.G., Zagoya, C., Polte, L., Naehrlich, L., Sasse, L., Eickmeier, O., Smaczny, C., Barucha, A., Bechinger, L., Duckstein, F., Eschenhagen, P., Kurzidim, L., Caley, L., Peckham, D., Schwarz, C. |
|---|---|
| Zdroj: | In Journal of Cystic Fibrosis June 2022 21 Supplement 1:S3-S3 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect